west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "周继陶" 4 results
  • Current Status of Treatment and Progress of Radiotherapy for Local Recurrence of Rectal Cancer

    Release date:2016-09-08 10:23 Export PDF Favorites Scan
  • 人表皮生长因子受体 2 在胃癌中的研究进展

    胃癌是我国常见的恶性肿瘤,晚期胃癌患者预后差,治疗疗效差,分子靶向治疗研究无疑将为晚期胃癌患者带来新的曙光。ToGA 研究为第一个获得晚期胃癌靶向治疗成功的临床研究,其将抗人表皮生长因子受体 2(human epidermal growth factor receptor,HER2)单克隆抗体曲妥珠单抗与化学疗法联合应用于晚期胃癌一线治疗。在 ToGA 研究之后,学者们对于胃癌抗 HER2 通路治疗的研究并未停止脚步,在精确筛选 HER2 阳性患者、HER2 阳性与患者预后、新的抗 HER2 治疗策略、治疗耐药机制及克服耐药策略等多方面取得了许多研究进展。该文针对 ToGA 研究之后胃癌 HER2 通路治疗的相关进展进行了综述。

    Release date:2017-08-22 11:25 Export PDF Favorites Scan
  • Clinical observation of gemcitabine plus tegafur, gimeracil and oteracil potassium in patients with metastatic castration-resistant prostate cancer after docetaxel failure

    Objective To observe the early efficacy and toxicity of gemcitabine plus tegafur, gimeracil and oteracil potassium (S-1) regimen (GS regimen) in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel failure. Methods From July 2013 to December 2015, sixteen mCRPC patients who failed in the treatment of docetaxel-based chemotherapy in West China Hospital of Sichuan University were collected. And the patients were treated with gemcitabine 1 000 mg/m2 intravenously on Day 1 and S-1 40–60 mg/m2 orally dividedly twice daily on Day 1–10, which repeated every two weeks. The main outcome measures were total prostate-specific antigen (T-PSA) decline rate and pain remission rate. Results Of the 13 evaluable patients, the T-PSA decline rate≥50% was observed in 4 patients (30.8%). Among the 11 patients with bone pain, remarkable pain relief was observed in 4 cases (36.4%). Myelosuppression, gastrointestinal reaction, rash and fatigue were the commonly observed adverse reactions and the toxicity of chemotherapy was tolerable. Conclusion The GS regimen is active and tolerable in patients with mCRPC after docetaxel failure.

    Release date:2017-11-24 10:58 Export PDF Favorites Scan
  • Whole process management of hepatocellular carcinoma patients with high-risk of recurrence and metastasis based on multidisciplinary team mode

    ObjectiveTo summarize the experience of the whole process management of hepatocellular carcinoma (HCC) patients with high-risk of recurrence and metastasis based on the multidisciplinary team (MDT) mode, and to improve the clinicians’ understanding of the concept of whole process management, so as to improve the survival rate of patients with HCC. MethodThe clinicopathologic data of a HCC patient with high-risk of recurrence and metastasis admitted to the Division of Liver Surgery, Department of General Surgery, West China Hospital of Sichuan University were retrospectively analyzed. ResultsA 52-year-old male patient was diagnosed with HCC with intrahepatic metastasis (China liver cancer staging Ⅱ b, Barcelona Clinic Liver Cancer stage B) after admission due to “epigastric discomfort for 1+-month and liver occupying for 1+-week”. Through discussion by the MDT mode, the allogeneic liver transplantation was performed after successful downstaging following two conversion therapies. No serious complications occurred after operation, and the patient was discharged on the 23rd day after operation. Up to now, pulmonary bacterial and fungal infections and pulmonary metastases had been found during the postoperative follow-up. After anti-infective therapy and targeted therapy combined with radiotherapy, the patient was significantly relieved, had survived for 34 months after operation, and was still under regular follow-up. ConclusionsFor HCC patients with high-risk of recurrence and metastasis, MDT mode has a good clinical benefit for the whole process management of patient. Through the MDT model, the diagnosis, treatment, and follow-up of HCC are organically integrated, and the patient’ s diagnosis and treatment plans are dynamically adjusted to realize the whole process management of HCC patient, and to raise the survival rate and improve quality of life of HCC patient.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content